Nymox Pharmaceutical Corporation

Nymox Pharmaceutical Corporation operates as a biopharmaceutical firm, primarily focused on the discovery and advancement of medications for the aging population across Canada, the United States, Europe, and other international regions.

The company's leading experimental compound is Fexapotide Triflutate (NX-1207), which has successfully concluded Phase III clinical trials for benign prostatic hyperplasia treatment.

It has also completed Phase II trials for localized low-grade prostate cancer and is currently in preclinical studies for hepatocellular carcinoma.

In addition to its drug pipeline, Nymox develops and markets diagnostic products. These include NicAlert and TobacAlert, tests that utilize urine or saliva samples to identify the use of tobacco products.

The company further offers AlzheimAlert, a proprietary urine-based assay designed to aid healthcare professionals in diagnosing Alzheimer's disease. Alongside this diagnostic tool, Nymox is actively researching and developing therapeutic treatments for Alzheimer's disease. Founded in 1989, the company is headquartered in Nassau, the Bahamas.